4/15
02:00 pm
crnx
Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer
Low
Report
Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer
4/8
04:05 pm
crnx
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
Low
Report
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
3/27
09:00 pm
crnx
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More [Yahoo! Finance]
Low
Report
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More [Yahoo! Finance]
3/26
04:05 pm
crnx
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
Medium
Report
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
3/23
03:55 pm
crnx
Crinetics Pharma COO to step down [Seeking Alpha]
Low
Report
Crinetics Pharma COO to step down [Seeking Alpha]
3/14
05:36 am
crnx
Is Crinetics Pharmaceuticals (CRNX) Pricing Reflect Its Sharp Swings And DCF Upside Potential [Yahoo! Finance]
Low
Report
Is Crinetics Pharmaceuticals (CRNX) Pricing Reflect Its Sharp Swings And DCF Upside Potential [Yahoo! Finance]
3/8
08:23 pm
crnx
Crinetics Pharmaceuticals Highlights Early PALSONIFY Sales, EU Milestone, and GPCR Pipeline at TD Cowen Conf. [Yahoo! Finance]
Low
Report
Crinetics Pharmaceuticals Highlights Early PALSONIFY Sales, EU Milestone, and GPCR Pipeline at TD Cowen Conf. [Yahoo! Finance]
3/2
09:27 am
crnx
Crinetics Pharmaceuticals (CRNX) had its price target lowered by Citizens Jmp from $105.00 to $96.00. They now have a "market outperform" rating on the stock.
Low
Report
Crinetics Pharmaceuticals (CRNX) had its price target lowered by Citizens Jmp from $105.00 to $96.00. They now have a "market outperform" rating on the stock.
2/26
10:12 pm
crnx
Crinetics Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Crinetics Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
07:22 pm
crnx
Crinetics (CRNX) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Crinetics (CRNX) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
2/26
04:22 pm
crnx
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
2/26
04:05 pm
crnx
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Medium
Report
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2/24
09:34 pm
crnx
Is Crinetics Pharmaceuticals (CRNX) Offering Value After Recent Share Price Pullback [Yahoo! Finance]
Medium
Report
Is Crinetics Pharmaceuticals (CRNX) Offering Value After Recent Share Price Pullback [Yahoo! Finance]
2/5
04:05 pm
crnx
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
Low
Report
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
1/26
05:00 pm
crnx
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Low
Report
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
1/22
05:00 pm
crnx
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) [Yahoo! Finance]
Medium
Report
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) [Yahoo! Finance]
1/22
04:05 pm
crnx
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Medium
Report
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)